IRIS
SANTANTONIO, TERESA ANTONIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.083
NA - Nord America 9.457
AS - Asia 5.861
Continente sconosciuto - Info sul continente non disponibili 69
SA - Sud America 21
OC - Oceania 14
AF - Africa 10
Totale 27.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.415
IE - Irlanda 4.161
CN - Cina 4.061
UA - Ucraina 3.147
SE - Svezia 1.699
IN - India 894
FR - Francia 875
IT - Italia 839
FI - Finlandia 655
TR - Turchia 655
GB - Regno Unito 267
DE - Germania 255
VN - Vietnam 122
AT - Austria 88
SG - Singapore 69
EU - Europa 68
RU - Federazione Russa 29
CA - Canada 28
BE - Belgio 22
NL - Olanda 15
MX - Messico 14
AU - Australia 11
PK - Pakistan 10
ES - Italia 9
IR - Iran 9
JP - Giappone 9
HK - Hong Kong 8
SY - Repubblica araba siriana 7
UY - Uruguay 7
CL - Cile 5
RO - Romania 5
BR - Brasile 4
CH - Svizzera 4
SA - Arabia Saudita 4
AR - Argentina 3
BG - Bulgaria 3
EG - Egitto 3
KR - Corea 3
NZ - Nuova Zelanda 3
RS - Serbia 3
TH - Thailandia 3
CZ - Repubblica Ceca 2
GH - Ghana 2
MY - Malesia 2
PE - Perù 2
PS - Palestinian Territory 2
PT - Portogallo 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BJ - Benin 1
GR - Grecia 1
ID - Indonesia 1
IQ - Iraq 1
KE - Kenya 1
KH - Cambogia 1
MK - Macedonia 1
ML - Mali 1
Totale 27.515
Salva come PNG Salva come JPEG
Città #
Dublin 4.159
Jacksonville 2.223
Dearborn 1.306
Chandler 1.218
Nanjing 1.156
Nyköping 877
Wilmington 661
Princeton 477
Beijing 465
Nanchang 444
San Mateo 370
Shenzhen 296
Shenyang 257
Helsinki 252
Ann Arbor 222
Tianjin 185
Kunming 178
Hebei 168
Ashburn 154
Changsha 138
Jiaxing 134
Hilden 133
Des Moines 127
Dong Ket 117
Hangzhou 95
Boardman 91
Stevenage 88
Vienna 85
Ningbo 79
Jinan 76
Woodbridge 73
Bari 70
Lanzhou 59
Zhengzhou 59
New York 55
Foggia 54
Guangzhou 40
Changchun 37
Taizhou 35
London 31
Orange 30
Rome 27
Los Angeles 26
Pune 26
Shanghai 25
Redwood City 24
Norwalk 23
Auburn Hills 20
Borås 20
Hefei 20
Brussels 19
Philadelphia 18
Rockville 16
Chengdu 14
Fuzhou 14
Washington 13
Chicago 11
Milan 11
Seattle 11
Falls Church 10
Meda 10
San Severo 10
Acquaviva Delle Fonti 9
Ankara 9
Redmond 9
Saint Petersburg 9
Singapore 9
Toronto 9
Augusta 8
Cutrofiano 8
Fairfield 8
Jinhua 8
Kocaeli 8
Tokyo 8
Gioia Del Colle 7
Hanover 7
Leawood 7
Marano Di Napoli 7
Montevideo 7
San Jose 7
Bitonto 6
Florence 6
Hidalgo 6
Lincoln 6
Madrid 6
Palermo 6
Torremaggiore 6
Trieste 6
Andover 5
Central 5
Gunzenhausen 5
Haikou 5
Hanoi 5
Melbourne 5
Mountain View 5
Napoli 5
Paris 5
Tehran 5
Brescia 4
Formello 4
Totale 17.392
Salva come PNG Salva come JPEG
Nome #
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. 354
Diagnosi rapida di sepsi: emocoltura e multiplex real time PCR a confronto 329
Epatite cronica anti-HBe/HBV DNA positiva e mutanti pre-core del virus dell'epatite B 172
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 152
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 124
HCV-related mixed cryoglobulinemia: data from PITER, a nationwide italian HCV cohort study 115
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 113
Health gains and costs of HCV treatment: a cost effectiveness analysis of two different health policies scenarios simulated in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) real life cohort 108
TERAPIA DELL'EPATITE ACUTA B e C 107
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 106
Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B. 103
National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing 100
Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. 98
Efficacy of a 24-week course of PEG-Interferon a-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. 97
Mucormicosi rino-orbitaria: una patologia da tenere d'occhio 96
Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic epatiti B 94
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 93
Natural course of acute hepatitis C: a long-term prospective study 91
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features 91
Tipizzazione fenotipica di Klebsiella Pneumoniae MDR mediante MALDI-TOFS MS in isolati clinici della Rianimazione A.O.U. OO. RR. Foggia 91
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 90
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 90
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant Chronic Hepatitis B 89
Comparison between HCV RNA and E1/E2 antibodies in patients on IFN treatment 89
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 88
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 88
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 88
The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? 87
Chronic viral hepatitis in patients with beta-thalassaemia minor. 86
Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. 84
Flares during long-term entecavir therapy in chronic hepatitis B 84
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 83
Non-A,non-B hepatitis virus. 82
Possible mechanisms involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. 82
Clinical and virological features of Hepatitis B and Delta infections in anti-HIV carriers 82
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 82
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 82
Correlation between knowledge on transmission and prevention of HIV/STI and proficiency in condom use among male migrants from Africa and Middle East evaluated by a Condom Use Skills score using a wooden penile model. 81
Feasibility of vaccination in preventing secondary cases of hepatitis A virus infection. 79
Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. 79
Acute hepatitis C: current status and remaining challenges. 79
Determinazione immunoenzimatica delle IgA specifiche anti-HAV nella diagnosi sierologica dell'epatite A 79
RIELISA: a new principle for the simultaneous detection of total and IgM antibodies. Application to hepatitis diagnosis 79
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 79
HCV-RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY 79
LE VARIANTI GENOMICHE DELLA REGIONE PRE-CORE DEL VIRUS DELL'EPATITE B: ASPETTI PATOGENETICI E CLINICI 79
Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. 78
Lack of HBV and HDV replicative activity in HBsAg-positive intravenous drug addicts with immune deficiency due to HIV. 78
Hepatitis B core antigen expression in chronic hepatitis B: correlation with serum HBV DNA detected by a biotinylated probe 78
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 78
Lamivudine/Interferon combination therapy in anti-HBe positive chronic hepatitis B patients; a controlled pilot study. 77
Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. 77
Clinical value of HIV p24 Ag in cerebrospinal fluid of symptomatic or asymptomatic HIV-infected patients 77
Diagnosi sierologica dell'epatite acuta da virus A. Messa a punto e valutazione di tre metodiche per la determinazione delle IgM specifiche anti-HAV 77
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 77
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 77
Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation 76
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 76
Role of HCV infection in the development of carotid atherosclerosis in a cohort of HIV-infected patients 76
Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF) 76
Predominance of HBV genotype D/HDV genotype 1 among chronically infected drug abusers in Italy 75
Association of HCV-specific -interferon producing CD8+ T cells with viral clearance in acute hepatitis C 75
Tenofovir suppressed viral suppression in most field practice, treatment-naive patients with CHB followed for 3 years in a multicenter European study 74
Long-term outcome of patients with HCV-related, Child’s class A cirrhosis treated with interferon-alpha (IFN): the impact of sustained virologic response (SVR) on hepatocellular carcinoma (HCC) occurrence and mortality 74
Selection of a secretion incompetent mutant in the serum of a patient with severe hepatitis B 73
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues 73
Treatment of acute hepatitis C with interferon alfa-2b. 73
Dendritic Cell Maturation in HCV Infection: Altered Regulation of MHC Class I Antigen Processing-Presenting Machinery 73
Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance. 73
Long-term response to interferon therapy in hepatitis B virus (HBV) pre-C mutants associated chronic hepatitis 73
Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. 72
Efficacia e tollerabilità della monoterapia con Entecavir (ETV) in pazienti con epatite cronica B 72
Male gender, genotype 3, previous alcohol use, increased BMI, and diabetes are factors independently correlated to advanced HCV chronic liver disease in Italy: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort study 72
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. 71
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. 71
Current Concepts on Management of Chronic Hepatitis BPractical Management of Chronic Viral Hepatitis 71
The course of anti-HBe/HBV-DNA positive chronic liver disease during long term lamivudine treatment 71
THE ITALIAN ENTAS COHORT STUDY: ENTECAVIR EFFECTIVENESS IN NAïVE AND TREATMENT EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B 71
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 71
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 71
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 71
High prevalence and heterogeneity of HBV pre-C mutants in anti-HBe-positive carriers with chronic liver disease in Southern Italy. 70
Virologic and clinical expression of reciprocal inhibitory effect of Hepatitis B, C, and Delta viruses in patients with chronic hepatitis 70
Valutazione di un test immunoenzimatico (ELISA) per la determinazione di un sistema Ag/Ab correlato all’epatite non-A,non-B post-trasfusionale 70
Cost-effectiveness of Tenofovir in the treatment of patients with chronic hepatitis B: data from literature 70
Clinical and histological outcome of extended lamivudine in patients with HBeAg negative chronic hepatitis B 70
Association of primary hepatocellular carcinoma (PHC) and a non-A,non-B related antigen./antibody system detected by Enzyme Linked Immunosorbent Assay (ELISA) 70
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. 70
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients 70
Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. 69
The use of molecular assays in the management of viral hepatitis. 69
Dosaggio radioimmunologico dell’HAV e delle IgA anti-HAV nelle feci di pazienti con epatite acuta di tipo A 69
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 69
Come trattare il paziente con non risposta o risposta virologica parziale 69
Detection of in vivo hepatitis B virus surface antigen mutations-a comparison of four routine screening assays 69
Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 68
Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease. 68
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 68
Gly145 to Arg substitution in HBs antigen of liver transplant patients receiving polyclonal hepatitis B immune globulin 68
Nuove strategie di trattamento 68
Totale 8.715
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.493
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.493
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019710 0 0 0 0 0 0 0 0 0 102 119 489
2019/20206.641 1.568 687 250 66 863 851 900 109 570 105 604 68
2020/20213.834 546 22 478 32 482 101 534 98 544 520 174 303
2021/20222.615 388 21 36 70 341 129 69 234 310 297 102 618
2022/20238.196 950 196 274 370 335 603 32 474 4.613 126 124 99
2023/20241.095 178 61 365 41 83 182 98 61 8 18 0 0
Totale 28.802